1. Home
  2. TBPH vs BIGC Comparison

TBPH vs BIGC Comparison

Compare TBPH & BIGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • BIGC
  • Stock Information
  • Founded
  • TBPH 2013
  • BIGC 2009
  • Country
  • TBPH United States
  • BIGC United States
  • Employees
  • TBPH N/A
  • BIGC N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • BIGC Computer Software: Prepackaged Software
  • Sector
  • TBPH Health Care
  • BIGC Technology
  • Exchange
  • TBPH Nasdaq
  • BIGC Nasdaq
  • Market Cap
  • TBPH 464.5M
  • BIGC 409.3M
  • IPO Year
  • TBPH N/A
  • BIGC 2020
  • Fundamental
  • Price
  • TBPH $8.91
  • BIGC $5.33
  • Analyst Decision
  • TBPH Buy
  • BIGC Hold
  • Analyst Count
  • TBPH 3
  • BIGC 7
  • Target Price
  • TBPH $11.33
  • BIGC $7.64
  • AVG Volume (30 Days)
  • TBPH 268.3K
  • BIGC 750.6K
  • Earning Date
  • TBPH 05-08-2025
  • BIGC 05-08-2025
  • Dividend Yield
  • TBPH N/A
  • BIGC N/A
  • EPS Growth
  • TBPH N/A
  • BIGC N/A
  • EPS
  • TBPH N/A
  • BIGC N/A
  • Revenue
  • TBPH $65,266,000.00
  • BIGC $334,937,000.00
  • Revenue This Year
  • TBPH $51.09
  • BIGC $5.65
  • Revenue Next Year
  • TBPH N/A
  • BIGC $5.48
  • P/E Ratio
  • TBPH N/A
  • BIGC N/A
  • Revenue Growth
  • TBPH 6.11
  • BIGC 5.33
  • 52 Week Low
  • TBPH $7.44
  • BIGC $4.85
  • 52 Week High
  • TBPH $10.90
  • BIGC $8.60
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 40.95
  • BIGC 50.14
  • Support Level
  • TBPH $8.69
  • BIGC $5.09
  • Resistance Level
  • TBPH $10.55
  • BIGC $5.59
  • Average True Range (ATR)
  • TBPH 0.38
  • BIGC 0.20
  • MACD
  • TBPH -0.12
  • BIGC 0.05
  • Stochastic Oscillator
  • TBPH 12.06
  • BIGC 58.06

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About BIGC BigCommerce Holdings Inc. Series 1

BigCommerce Holdings Inc is engaged in offering Software-as-a-service (SaaS) e-commerce platform. The company's SaaS platform engages in the creation of online stores by delivering a combination of ease-of-use, enterprise functionality, and flexibility. It powers both the customers' branded ecommerce stores and their cross-channel connections to popular online marketplaces, social networks, and offline point-of-sale systems. The group operates in a single segment covering geographical areas of Americas-U.S.; Americas-other; EMEA; and APAC, of which majority of revenue is generated from Americas-U.S.

Share on Social Networks: